Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaxis Ltd ( (AU:SNT) ) just unveiled an update.
Syntara Limited has commenced dosing the first participant in its Phase 1a/b clinical trial for SNT-9465, a next-generation topical anti-fibrotic drug aimed at treating hypertrophic scars. This trial will assess the drug’s safety and tolerability, with results expected in the first half of 2026. The trial’s outcomes could lead to an FDA Investigational New Drug application, potentially establishing SNT-9465 as the first approved pharmacological treatment for skin scarring, addressing a significant unmet need in the market.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focused on creating first-in-class drugs. The company is actively engaged in multiple clinical trials targeting high-value commercial opportunities, particularly in the treatment of skin scarring.
Average Trading Volume: 9,888,378
Technical Sentiment Signal: Sell
Current Market Cap: A$91.05M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.